MILAN — At the ESCRS meeting, Shigeru Kinoshita, MD, PhD, joined virtually a symposium on emerging treatment options for corneal endothelial disease.
In this video perspective, he speaks about the results of his second-generation cell injection therapy supplemented by a ROCK inhibitor, a regenerative medicine technology that proved successful in studies for both Fuchs’ dystrophy and bullous keratopathy.